Vimpat · DIN 02357631 · 150 mg · tablet
Limited Use, Reason for Use code 430 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 430 required
Write on scriptReason for Use code 430 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 430
Reason for Use code 430
As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND
Patients are under the care of a physician experienced in the treatment of epilepsy.
Note: Less costly anticonvulsant therapies may include the following:
Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Vimpat · DIN 02357631
Manufacturer: UCB Canada Inc.; listing date 2012-04-24
Health Canada: Marketed since 2010-10-21 · brand VIMPAT · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 150 MG · company Ucb canada inc · schedule Prescription
Ministry pays: $1.1763 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02357631)
Source record
DIN 02357631: Vimpat
Raw flags: sec12=Y, sec3=Y
Item: 281200150; group id 431; item number 1077; lccId 00221; manufacturer id UCB
Source form: Tab; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $4.7050; ministry $1.1763
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02357631
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84274
Interchangeable products
Ach-Lacosamide · DIN 02489309 · $1.1763
Auro-Lacosamide · DIN 02475359 · $1.1763
Jamp-Lacosamide · DIN 02488418 · $1.1763
Lacosamide · DIN 02512890 · $1.1763
Mint-Lacosamide · DIN 02490560 · $1.1763
NRA-Lacosamide · DIN 02499584 · $1.1763
Pharma-Lacosamide · DIN 02478226 · $1.1763
Sandoz Lacosamide · DIN 02474697 · $1.1763
Teva-Lacosamide · DIN 02472929 · $1.1763
ZDS-Lacosamide · DIN 02487829 · $1.1763
Shortage status: resolved shortage (ended March 20, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357631
Shortage record checked October 6, 2026